---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-015856"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:10:42.373634+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx FY2023 revenue $434M (+20% YoY); net loss narrows; 2024 guide $500-530M

## Summary
- Total revenue 2023 $434M (+20% YoY); Crysvita $328M (+17%), Dojolvi $71M (+27%).
- Net loss 2023 $607M ($8.25/sh) vs $707M ($10.12) in 2022; Q4 loss $123M ($1.52).
- Cash $777M at Dec 31, 2023; 2024 net cash used in ops expected <$400M.
- 2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M.
- Pipeline: DTX401 GSDIa Ph3 data H1 2024; GTX-102 Angelman expansion data H1 2024; setrusumab OI Ph3 enrollment Q1 end.

## SEC filing metadata
- accession: 0000950170-24-015856
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/0000950170-24-015856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/rare-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-015856
- JSON: https://secwatch.observer/filing/0000950170-24-015856.json
- Plain text: https://secwatch.observer/filing/0000950170-24-015856.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).
  - Period: the quarter and full year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 15, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2023 and the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/0000950170-24-015856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.